Shattuck Labs (STTK) Competitors $1.11 -0.03 (-2.63%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends STTK vs. SOPH, ZNTL, GNFT, SLN, INBX, ZURA, EDIT, SLDB, XBIT, and CRBPShould you be buying Shattuck Labs stock or one of its competitors? The main competitors of Shattuck Labs include SOPHiA GENETICS (SOPH), Zentalis Pharmaceuticals (ZNTL), Genfit (GNFT), Silence Therapeutics (SLN), Inhibrx (INBX), Zura Bio (ZURA), Editas Medicine (EDIT), Solid Biosciences (SLDB), XBiotech (XBIT), and Corbus Pharmaceuticals (CRBP). These companies are all part of the "pharmaceutical products" industry. Shattuck Labs vs. SOPHiA GENETICS Zentalis Pharmaceuticals Genfit Silence Therapeutics Inhibrx Zura Bio Editas Medicine Solid Biosciences XBiotech Corbus Pharmaceuticals SOPHiA GENETICS (NASDAQ:SOPH) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, community ranking, earnings and institutional ownership. Which has preferable earnings & valuation, SOPH or STTK? SOPHiA GENETICS has higher revenue and earnings than Shattuck Labs. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSOPHiA GENETICS$62.37M3.32-$78.98M-$1.09-2.91Shattuck Labs$1.66M31.92-$87.30M-$1.53-0.73 Do analysts rate SOPH or STTK? SOPHiA GENETICS presently has a consensus price target of $6.50, suggesting a potential upside of 105.05%. Shattuck Labs has a consensus price target of $8.67, suggesting a potential upside of 680.78%. Given Shattuck Labs' higher probable upside, analysts clearly believe Shattuck Labs is more favorable than SOPHiA GENETICS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SOPHiA GENETICS 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Shattuck Labs 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.40 Does the media favor SOPH or STTK? In the previous week, Shattuck Labs had 10 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 12 mentions for Shattuck Labs and 2 mentions for SOPHiA GENETICS. SOPHiA GENETICS's average media sentiment score of 0.00 beat Shattuck Labs' score of -0.03 indicating that SOPHiA GENETICS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SOPHiA GENETICS 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Shattuck Labs 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, SOPH or STTK? SOPHiA GENETICS has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Shattuck Labs has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500. Does the MarketBeat Community prefer SOPH or STTK? Shattuck Labs received 19 more outperform votes than SOPHiA GENETICS when rated by MarketBeat users. However, 72.00% of users gave SOPHiA GENETICS an outperform vote while only 71.15% of users gave Shattuck Labs an outperform vote. CompanyUnderperformOutperformSOPHiA GENETICSOutperform Votes1872.00% Underperform Votes728.00% Shattuck LabsOutperform Votes3771.15% Underperform Votes1528.85% Do insiders & institutionals believe in SOPH or STTK? 31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by insiders. Comparatively, 10.5% of Shattuck Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is SOPH or STTK more profitable? SOPHiA GENETICS has a net margin of -110.71% compared to Shattuck Labs' net margin of -1,156.46%. SOPHiA GENETICS's return on equity of -55.06% beat Shattuck Labs' return on equity.Company Net Margins Return on Equity Return on Assets SOPHiA GENETICS-110.71% -55.06% -38.33% Shattuck Labs -1,156.46%-61.92%-54.49% SummarySOPHiA GENETICS beats Shattuck Labs on 10 of the 19 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Shattuck Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for STTK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STTK vs. The Competition Export to ExcelMetricShattuck LabsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$52.99M$6.45B$5.06B$8.82BDividend YieldN/A8.11%5.18%4.07%P/E Ratio-0.7310.78126.3117.81Price / Sales8.23243.711,178.7474.57Price / CashN/A22.1633.8632.53Price / Book0.335.474.684.68Net Income-$87.30M$153.61M$119.54M$226.08M7 Day Performance-18.98%-2.00%-1.83%-1.04%1 Month Performance-11.20%-7.46%-3.60%1.04%1 Year Performance-51.53%31.82%31.91%26.28% Shattuck Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STTKShattuck Labs2.8247 of 5 stars$1.11-2.6%$8.67+680.8%-50.7%$54.42M$1.66M-0.73100Analyst RevisionSOPHSOPHiA GENETICS1.4237 of 5 stars$3.17-3.1%$6.50+105.0%-14.6%$213.78M$62.37M0.00520ZNTLZentalis Pharmaceuticals2.5896 of 5 stars$3.13+4.7%$10.00+219.5%-71.1%$213.08MN/A0.00160Analyst RevisionGNFTGenfit1.4608 of 5 stars$4.31+1.2%$13.00+201.6%+27.1%$212.95M$41.31M0.00120SLNSilence Therapeutics3.646 of 5 stars$6.93-0.6%$57.20+725.4%-27.1%$208.60M$31.55M0.00100Analyst ForecastNews CoverageHigh Trading VolumeINBXInhibrx1.2884 of 5 stars$14.04-1.7%N/A-36.9%$206.86M$1.63M0.00166ZURAZura Bio3.9055 of 5 stars$2.90-7.9%$15.80+444.8%-35.1%$205.68MN/A0.003Analyst ForecastEDITEditas Medicine4.7809 of 5 stars$2.41-2.8%$9.08+276.9%-77.8%$204.72M$78.12M-0.94230Short Interest ↓SLDBSolid Biosciences3.3235 of 5 stars$4.96-2.9%$15.14+205.3%+108.4%$204.17M$8.09M-1.63100Analyst RevisionXBITXBiotech0.8946 of 5 stars$6.49-2.7%N/A+77.8%$203.32M$4.01M-6.01100Positive NewsCRBPCorbus Pharmaceuticals4.8781 of 5 stars$16.08-2.9%$65.86+309.6%+249.6%$201.69M$880,000.00-3.4340Positive News Related Companies and Tools Related Companies SOPHiA GENETICS Competitors Zentalis Pharmaceuticals Competitors Genfit Competitors Silence Therapeutics Competitors Inhibrx Competitors Zura Bio Competitors Editas Medicine Competitors Solid Biosciences Competitors XBiotech Competitors Corbus Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:STTK) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shattuck Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Shattuck Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.